COVID-19

BLUFFDALE, Utah, May 12, 2022  — Med 7, LLC (www.med7cbd.com) and HempCo, Inc. announce the completion and publication of the first prospective human clinical study to assess the effects of a CBD-rich full-spectrum hemp oil in patients with COVID-19 (SARS-CoV-2). The study used Med 7®, a full-spectrum hemp product made with Purzorb® technology, now trademarked as Hempzorb81™. “We are extremely fortunate to publish the first prospective, double-blind, placebo-controlled human clinical trial with a CBD-rich full-spectrum hemp oil in patients who test positive for COVID,” said Matt Smith, CEO of Med 7. “We were in the initial stages of our study of Med 7 in 150 patients with Type 2 Diabetes, when COVID hit our study population hard. Rather than discontinuing the study, we decided to keep going to see if Med 7 had any impact on those who tested positive for COVID. This was in early 2020 when no one knew much about the physiological effects of COVID, so we were not even sure at first what to study other than mortality and hospitalization rates. Since we had seen significantly positive effects of Hempzorb81™ on cytokines (inflammatory markers) in a previous safety and efficacy study, we decided to look at those markers again, as well as white blood cell counts, to see what was going on in the immune system,” explained Smith.[Read more…] about MED 7 LLC AND HEMPCO IC. ANNOUNCE THE PUBLICATION OF THE FIRST PROSPECTIVE HUMAN CLINICAL TRIAL USING A CBD-RICH FULL-SPECTRUM HEMP OIL IN PATIENTS WITH COVID-19